Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Minerva Neurosciences, Inc (NERV : NSDQ)

• Company Description    Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company's pipeline will initially target the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson's disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301. Minerva Neurosciences, Inc. is based in Cambridge, MA, United States. Number of Employees: 8

• Price / Volume Information    Yesterday's Closing Price: $2.18 Daily Weekly Monthly 20 Day Moving Average: 40,001 shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: -0.25 52 Week High: $3.00 52 Week Low: $1.15 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 21.45% 19.31% 12 Week 20.44% 9.40% Year To Date -1.87% -14.40%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1500 DISTRICT AVE - BURLINGTON,MA 01803 USA ph: 617-600-7373 fax: - info@minervaneurosciences.com http://www.minervaneurosciences.com

• General Corporate Information    Officers Remy Luthringer - Executive Chairman and Chief Executive Officer Geoffrey Race - President Frederick Ahlholm - Chief Financial Officer Hans Peter Hasler - Member of the Board of Directors David Kupfer - Member of the Board of Directors Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 603380205 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/04/25 Share - Related Items Shares Outstanding: Most Recent Split Date: 6.00 (0.13:1) Beta: -0.25 Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.35 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.68 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 1.47 PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: 10.43 Price / Sales: - EPS Growth vs. Year Ago Period: 60.55% vs. Previous Quarter: 14.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -41.35 03/31/25 - -20.68 12/31/24 - -4.48 ROA 06/30/25 - 31.37 03/31/25 - 15.73 12/31/24 - 3.26 Current Ratio 06/30/25 - 6.15 03/31/25 - 9.21 12/31/24 - 7.85 Quick Ratio 06/30/25 - 6.15 03/31/25 - 9.21 12/31/24 - 7.85 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - -4.59 03/31/25 - -4.17 12/31/24 - -3.67 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©